leisure time -WSS

leisure time

author：focus 2025-08-12 09:11:51 - browse：76362

Venture capital firm RA Capital is starting a new incubator, setting the stage for the firm to create new startups over the next several years that hone in on synthetic biology, a long-gestating field that insiders say is getting renewed interest.

The Boston-based VC’s incubator is called RASyn, and will be led by Robert Nicol, according to people familiar with the firm’s plans. Nicol spent more than 20 years at the Broad Institute, where he co-founded the MIT-Broad Foundry for Synthetic Biology, as well as HiFiBio Therapeutics and Design Pharmaceuticals.

RA Capital confirmed RASyn’s existence. Senior Managing Director Josh Resnick told STAT it’s part of the firm’s work to rethink how it develops platforms — core technologies or scientific approaches that underpin all of the drugs a biotech develops — but declined to comment further.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Tome Biosciences co

knowledge

explore

WSS

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Why Eli Lilly’s earnings didn’t quite live up to the hype

STAT Boddities: What happens to the brain when we get scared?

Prosthetic arm enables patients to feel the objects they grip

Study gives hint on South Asians’ higher risk of cardiovascular disease

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

focus

leisure time

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Wildfire smoke exposes gaps in outdoor worker protections

Addiction doctors spar with methadone clinics over legislation

Sports medicine is finally prioritizing gender equality

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

In age of alternative facts, a scholarly course on calling out crap

Ebola vaccine can save some who are already sick, per new study

Wildfire smoke exposes gaps in outdoor worker protections

Study gives hint on South Asians’ higher risk of cardiovascular disease

entertainment

Insmed lung disease drug hits target in key Phase 3 trial

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

What will save rural psychiatry services? Higher Medicaid payments

Why don't Americans have at

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

knowledge

explore

explore

focus